Calidi Biotherapeutics

Novel oncology platform targeting solid tumors with precision virotherapy. Building toward clinical validation.

NYSEAMERICAN: $CLDI

[Calidi Biotherapeutics @CalidiBio]

$CLDI's CEO Eric Poma joined the @NanoCapPod to discuss Calidi's oncolytic virus platform, its potential to transform cancer treatment, and the Company's clinical strategy.

Listen:
@Spotify: https://t.co/eVX5gXc2yX
@ApplePodcasts: https://t.co/TjX1IGBt0p

[Calidi Biotherapeutics @CalidiBio]

$CLDI's CEO, Dr. Eric Poma, will participate in an investor webinar hosted by @RedChip on June 9, at 1:15pm PT. Dr. Poma will share an in-depth overview of Calidi's breakthrough RedTail platform & highlight the progress of its lead candidate, CLD-401.

🔗 https://t.co/xCakwm1qMb

[Calidi Biotherapeutics @CalidiBio]

June is #NationalCancerSurvivorMonth, a time to honor the strength and resilience of cancer survivors, caregivers, and families impacted by cancer.

Their journeys continue to inspire advances in targeted immunotherapies for difficult-to-treat cancers.

$CLDI

[Calidi Biotherapeutics @CalidiBio]

Dr. Eric Poma has served as $CLDI's CEO and Director since April 2025.

Dr. Poma brings over three decades of experience in the biopharmaceutical industry, including clinical program development, big pharma collaboration agreements, and a strong record of capital fundraising.

[Calidi Biotherapeutics @CalidiBio]

Last week’s earnings release highlighted recent milestones across $CLDI's RedTail platform and pipeline programs, including new @AACR and @ASGCTherapy presentations and continued advancement of CLD-401.

Get the full Q1 update here: https://t.co/e2mjbnJRPj

[Calidi Biotherapeutics @CalidiBio]

$CLDI announces that two abstracts showcasing its RedTail platform have been accepted for online publication at @ASCO 2026. The company will present preclinical data on its lead program, CLD-401.

Full press release here: https://t.co/kzWHODWJ5v

#ASCO26

[Calidi Biotherapeutics @CalidiBio]

This #ClinicalTrialsDay, $CLDI recognizes the patients, investigators, clinicians, & researchers advancing clinical research. The Calidi team is focused on engineering the future of genetic medicine through our proprietary platforms.

More on our pipeline: https://t.co/7KRnvjzJsI

[Calidi Biotherapeutics @CalidiBio]

$CLDI reports its first quarter 2026 operating and financial results and reviews recent business highlights.

Full press release here: https://t.co/e2mjbnJRPj

[Calidi Biotherapeutics @CalidiBio]

$CLDI's CSO and Head of Technical Operations, Dr. Antonio F. Santidrian, will detail the exciting promise of our RedTail platform and present new data on its first lead, CLD-401, at the annual @ASGCTherapy conference

Full press release here: https://t.co/lPtiyvus2T

#ASGCT2026

[Calidi Biotherapeutics @CalidiBio]

$CLDI's RedTail platform is genetically engineered to avoid immune clearance, enabling systemic administration. Since replication only occurs in tumor cells, the delivery of genetic medicines is precisely targeted to the tumor.

Learn about RedTail’s MOA: https://t.co/eGrq7lNiMl

[Calidi Biotherapeutics @CalidiBio]

$CLDI is engineering the future of genetic medicine, delivering therapies precisely to sites of disease to advance oncology and other indications.

Learn more about our unique approach to precisely delivering genetic medicines to sites of disease: https://t.co/d7aGHIWo4S

[Calidi Biotherapeutics @CalidiBio]

📣 We are excited to announce that CEO, Dr. Eric Poma, will be presenting at the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8–10, 2025 at the Lotte New York Palace Hotel in NYC.

Read more here: https://t.co/DgsnNNCSWZ

#calidi #redtail $CLDI

[Calidi Biotherapeutics @CalidiBio]

We are thrilled to announce that CLD‑201 (SuperNova), our allogeneic adipose stem-cell loaded oncolytic virus, has received FDA Fast Track designation for the treatment of patients with soft tissue sarcoma.

Read more here: https://t.co/0Hvew1jfQS

#CLD201 #calidi #FastTrack

[Calidi Biotherapeutics @CalidiBio]

We are excited to announce a shareholder letter from CEO, Eric Poma, PhD, highlighting changes in Calidi's leadership, its focus and priorities, and in its balance sheet and operating expenses.

Read more here: https://t.co/oEff9avOsH

#calidi #redtail #virotherapy $CLDI

[Calidi Biotherapeutics @CalidiBio]

Calidi Biotherapeutics CEO, Eric Poma, represented the company at the BIO conference in Boston last week! Dr. Poma had a series of productive meetings that highlighted Calidi’s innovative approach and deep commitment to advancing immuno-oncology.

#calidi #virotherapy #BIO $CLDI

[Calidi Biotherapeutics @CalidiBio]

@CalidiBio today announced the presentation of its lead RedTail platform candidate, CLD-401, at the American Society of Clinical Oncology @ASCO Annual Meeting.

Read more here: https://t.co/KYxBPNvd5a

#calidi #redtail #systemic #asco $CLDI

[Calidi Biotherapeutics @CalidiBio]

📣 Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights

Read more to learn about Calidi's recent corporate developments: https://t.co/yrQlRAbwHq

#calidi #redtail #virotherapy $CLDI

[Calidi Biotherapeutics @CalidiBio]

@CalidiBio today announced the succession of its CEO, Allan Camaisa, to Eric Poma, Ph.D., who was appointed as CEO and member of the Board of Directors of Calidi. Mr. Camaisa will continue to serve as a member of the Board.

Read more here: https://t.co/HDxpwgknV3

[Calidi Biotherapeutics @CalidiBio]

We are thrilled to announce the appointment of Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor.

Read more here: https://t.co/hZaH10iUSF

[Calidi Biotherapeutics @CalidiBio]

@CalidiBio is pleased to report fourth quarter and full-year 2024 financial results and recent operational highlights. These include:

Read more about these exciting updates here: https://t.co/49YDydZSOI